Merck (MRK) Tops Q2 EPS by 12c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Merck (MRK) tops earnings, revenue expectations but guidance mixed
July 30, 2024 6:49 AM EDT(Updated - July 30, 2024 10:02 AM EDT)
Merck (NYSE: MRK) reported a robust second quarter, with adjusted earnings per share (EPS) of $2.28, surpassing analysts' predictions by $0.12. The pharmaceutical giant also exceeded revenue expectations, posting $16.11 billion against a $15.85 billion consensus.
However, the company's stock has fallen by more than 6% following the report.
The company's chairman and CEO, Robert Davis, attributed the strong quarterly performance to "excellent scientific, commercial and operational execution," highlighting the successful U.S. launch of WINREVAIR and positive European opinions for adults with pulmonary... More
